Cancer Letters
Volume 294, Issue 1 , Pages 91-100 , 1 August 2010

TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway

  • Dengfeng Wang

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, PR China
    • Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Brisbane, Qld 4072, Australia
    • ,
  • Jenny Nga Ting Fung

      Affiliations

    • Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Brisbane, Qld 4072, Australia
    • ,
  • Ya Tuo

      Affiliations

    • Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Brisbane, Qld 4072, Australia
    • Department of Forensic Sciences, College of Medicine, Xi’an Jiaotong University, Xi’an 710061, PR China
    • ,
  • Lina Hu

      Affiliations

    • Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu 610041, PR China
    • Corresponding Author InformationCorresponding authors. Tel.: +86 28 85502391; fax: +86 28 85503776 (L. Hu), tel.: +61 07 33653856; fax: +61 07 33652398 (C. Chen).
    • ,
  • Chen Chen

      Affiliations

    • Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Brisbane, Qld 4072, Australia
    • Corresponding Author InformationCorresponding authors. Tel.: +86 28 85502391; fax: +86 28 85503776 (L. Hu), tel.: +61 07 33653856; fax: +61 07 33652398 (C. Chen).

Received 8 December 2009 ,Revised 19 January 2010 ,Accepted 21 January 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005;55:74–108
  2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505
  3. Sorosky JI. Endometrial cancer. Obstet. Gynecol. 2008;111:436–447
  4. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J. Clin. 2003;53:27–43
  5. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J. Clin. Oncol. 2003;21:3526–3534
  6. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 1997;272:32401–32410
  7. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837–846
  8. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J. Biol. Chem. 1999;274:33166–33176
  9. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 2006;281:13964–13971
  10. Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem. J. 2006;397:297–304
  11. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler. Thromb. Vasc. Biol. 2003;23:594–600
  12. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem. 1999;274:8455–8459
  13. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J. Clin. Invest. 2005;115:2330–2340
  14. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem. 2005;280:3483–3492
  15. Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, et al. Dual role for TWEAK in angiogenic regulation. J. Cell Sci. 2002;115:267–274
  16. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 2002;299:488–493
  17. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am. J. Pathol. 2003;162:1313–1321
  18. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J. Neurosci. 2004;24:8237–8244
  19. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur. J. Immunol. 1999;29:1785–1792
  20. Wilson CA, Browning JL. Death of HT 29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ. 2002;9:1321–1333
  21. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, et al. Multiple pathways of TWEAK-induced cell death. J. Immunol. 2002;168:734–743
  22. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J. Immunol. 2003;170:341–348
  23. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, et al. TWEAK is a novel arthritogenic mediator. J. Immunol. 2006;177:2610–2620
  24. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J. Biol. Chem. 2003;278:32317–32323
  25. Dogra C, Changotra H, Mohan S, Kumar A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem. 2006;281:10327–10336
  26. Felli N, Pedini F, Zeuner A, Petrucci E, Testa U, Conticello C, et al. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J. Immunol. 2005;175:1464–1472
  27. Winkles JA, Tran NL, Brown SA, Stains N, Cunliffe HE, Berens ME. Role of TWEAK and Fn14 in tumor biology. Front. Biosci. 2007;12:2761–2771
  28. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res. 2004;64:8968–8972
  29. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell. 2004;15:2523–2536
  30. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human colonic adenocarcinoma cells. Int. J. Oncol. 2005;26:87–93
  31. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem. Biophys. Res. Commun. 2004;318:726–733
  32. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett’s metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene. 2006;25:3346–3356
  33. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am. J. Pathol. 2000;156:1253–1261
  34. Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene. 2005;24:2613–2624
  35. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi. 1985;37:1103–1111
  36. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 1972;114:1012–1019
  37. Kuramoto H. Studies of the growth and cytogenetic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet. Gynaecol. Jpn. 1972;19:47–58
  38. Richardson GS, Dickersin GR, Atkins L, MacLaughlin DT, Raam S, Merk LP, et al. KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol. Oncol. 1984;17:213–230
  39. Inta I, Frauenknecht K, Dorr H, Kohlhof P, Rabsilber T, Auffarth GU, et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J. Neurol. Sci. 2008;275:117–120
  40. Coussens AK, Hughes IP, Wilkinson CR, Morris CP, Anderson PJ, Powell BC, et al. Identification of genes differentially expressed by prematurely fused human sutures using a novel in vivo–in vitro approach. Differentiation. 2008;76:531–545
  41. McCulloch DR, Akl P, Samaratunga H, Herington AC, Odorico DM. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin. Cancer Res. 2004;10:314–323
  42. Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, Coons SW, et al. Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res. 2001;61:4190–4196
  43. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem. J. 2003;371:395–403
  44. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int. J. Cancer. 2007;121:2132–2139
  45. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J. Biol. Chem. 2003;278:36005–36012
  46. Xu H, Okamoto A, Ichikawa J, Ando T, Tasaka K, Masuyama K, et al. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem. Biophys. Res. Commun. 2004;318:422–427
  47. Dai L, Gu L, Ding C, Qiu L, Di W. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett. 2009;283:159–167
  48. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol. Oncol. 2008;109:394–402
  49. Castelbaum AJ, Ying L, Somkuti SG, Sun J, Ilesanmi AO, Lessey BA. Characterization of integrin expression in a well differentiated endometrial adenocarcinoma cell line (Ishikawa). J. Clin. Endocrinol. Metab. 1997;82:136–142
  50. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit. Rev. Oncog. 1999;10:303–360
  51. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348
  52. Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria?. Cancer Biol. Ther. 2006;5:763–765
  53. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  54. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein–protein interaction between TWEAK and CD163: potential biological implications. J. Immunol. 2007;178:8183–8194
  55. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J. Immunol. 2000;164:2897–2904
  56. Sporn MB. The war on cancer. Lancet. 1996;347:1377–1381
  57. Bayascas JR, Yuste VJ, Benito E, Garcia-Fernandez J, Comella JX. Isolation of AmphiCASP-3/7, an ancestral caspase from amphioxus (Branchiostoma floridae). Evolutionary considerations for vertebrate caspases. Cell Death Differ. 2002;9:1078–1089
  58. Garcia-Calvo M, Peterson EP, Rasper DM, Vaillancourt JP, Zamboni R, Nicholson DW, et al. Purification and catalytic properties of human caspase family members. Cell Death Differ. 1999;6:362–369
  59. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem. Sci. 1997;22:299–306
  60. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 1997;272:17907–17911
  61. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312–1316
  62. Le DA, Wu Y, Huang Z, Matsushita K, Plesnila N, Augustinack JC, et al. Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc. Natl. Acad. Sci. USA. 2002;99:15188–15193
  63. Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR. Apoptotic mechanisms in T 47D and MCF-7 human breast cancer cells. Br. J. Cancer. 2002;87:909–917
  64. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del Rio G, et al. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J. Biol. Chem. 2002;277:21836–21842
  65. McStay GP, Salvesen GS, Green DR. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 2008;15:322–331
  66. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 1999;15:269–290

PII: S0304-3835(10)00053-4

doi: 10.1016/j.canlet.2010.01.027

Cancer Letters
Volume 294, Issue 1 , Pages 91-100 , 1 August 2010

Article Tools

* Image Usage & Resolution